DrugId:  1
1. Name:  FP0011
2. Groups:  Investigational
3. Description:  FP0011 is a small molecule antiglutamatergic compound with symptomatic and disease modifying effects in a variety of neurological disorders (amyotrophic lateral sclerosis and Parkinson's disease). It acts on the presynaptic regulation of glutamate and shows strong neuroprotective properties.
4. Indication:  Investigated for use/treatment in amyotrophic lateral sclerosis (ALS) and parkinson's disease.
DrugId:  2
1. Name:  Dulaglutide
2. Groups:  Approved, Investigational
3. Description:  Dulaglutide is a novel glucagon-like peptide-1 agonist (GLP-1) biologic drug consisting of a dipeptidyl peptidase-IV-protected GLP-1 analogue covalently linked to a human IgG4-Fc heavy chain by a small peptide linker. Dulaglutide is indicated in the treatment of type 2 diabetes and can be used once a week. It was approved by the FDA in September 2014. Dulaglutide is manufactured and marketed by Eli Lily under the brand Trulicity™. It is not known if dulaglutide can increase the risk of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, and is thus not recommended for use in populations with a personal or family history of these conditions. 
4. Indication:  Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
DrugId:  3
1. Name:  Vandetanib
2. Groups:  Approved
3. Description:  Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types.On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients.
4. Indication:  Vandetanib is currently approved as an alternative to local therapies for both unresectable and disseminated disease. Because Vandetanib can prolong the Q-T interval, it is contraindicated for use in patients with serious cardiac complications such as congenital long QT syndrome and uncompensated heart failure. 
DrugId:  4
1. Name:  Ozanezumab
2. Groups:  Investigational
3. Description:  Ozanezumab has been used in trials studying the treatment of Multiple Sclerosis, Amyotrophic Lateral Sclerosis, and Multiple Sclerosis, Relapsing-Remitting.
4. Indication:  Not Available
DrugId:  5
1. Name:  Rovalpituzumab Tesirine
2. Groups:  Investigational
3. Description:  Rovalpituzumab Tesirine has been used in trials studying the treatment of GLIOBLASTOMA, Malignant Melanoma, Other Solid Tumors, Small Cell Lung Cancer, and Medullary Thyroid Cancer, among others.
4. Indication:  Not Available
DrugId:  6
1. Name:  RPI-78M
2. Groups:  Investigational
3. Description:  RPI-78M is being developed for the treatment of multiple sclerosis (MS). Other neurological disorders that may be served by RPI-78M include myasthenia gravis (MG), muscular dystrophy (MD) and amyotrophic lateral sclerosis (ALS).
4. Indication:  Investigated for use/treatment in multiple sclerosis, neurologic disorders, and pain (acute or chronic).
DrugId:  7
1. Name:  ALS-08
2. Groups:  Investigational
3. Description:  ALS-08 is a proprietary creatine-derivative that is being developed as a potential therapeutic for amyotrophic lateral sclerosis (ALS). It is being developed by Avicena Group, Inc.
4. Indication:  Investigated for use/treatment in amyotrophic lateral sclerosis (ALS).
DrugId:  8
1. Name:  QR-334
2. Groups:  Investigational
3. Description:  QR-334 is under investigation for the treatment of sialorrhea. Sialorrhea is an excess secretion of saliva produced by the salivary glands, resulting in drooling. No pharmaceutical interventions currently exist to treat sialorrhea. The symptom is associated with many diseases including Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s Disease, Cerebral Palsy, Parkinson's Disease, and Muscular Dystrophy.
4. Indication:  Investigated for use/treatment in saliva and salivary gland dysfunction (sialorrhea).
DrugId:  9
1. Name:  Ondansetron
2. Groups:  Approved
3. Description:  A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties. [PubChem]
4. Indication:  For the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, postoperation, and radiation. Also used for the treatment of postoperative nausea and vomiting.
DrugId:  10
1. Name:  Telbermin
2. Groups:  Investigational
3. Description:  Telbermin has been used in trials studying the treatment of Foot Ulcer, Foot Ulcer, Diabetic, and Amyotrophic Lateral Sclerosis.
4. Indication:  Not Available
DrugId:  11
1. Name:  Granisetron
2. Groups:  Approved, Investigational
3. Description:  A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients. [PubChem]
4. Indication:  For the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy (including high dose cisplatin), postoperation, and radiation (including total body irradiation and daily fractionated abdominal radiation).
DrugId:  12
1. Name:  Tirasemtiv
2. Groups:  Investigational
3. Description:  Tirasemtiv has been used in trials studying the treatment of Myasthenia Gravis, Intermittent Claudication, and Amyotrophic Lateral Sclerosis.
4. Indication:  Not Available
DrugId:  13
1. Name:  AEOL 10150
2. Groups:  Investigational
3. Description:  AEOL 10150 is developed by Aeolus as a therapeutic agents based on its proprietary small molecule catalytic antioxidants. 
4. Indication:  Investigated for use/treatment in amyotrophic lateral sclerosis (ALS).
DrugId:  14
1. Name:  Riluzole
2. Groups:  Approved, Investigational
3. Description:  A glutamate antagonist (receptors, glutamate) used as an anticonvulsant (anticonvulsants) and to prolong the survival of patients with amyotrophic lateral sclerosis. Riluzole is marketed as Rilutek by Sanofi. 
4. Indication:  For the treatment of amyotrophic lateral sclerosis (ALS, Lou Gehrig's Disease)
DrugId:  15
1. Name:  Arimoclomol
2. Groups:  Investigational
3. Description:  Arimoclomol is an experimental drug compound developed by CytRx Corporation, a biopharmaceutical company based in Los Angeles, California. The orally administered drug is intended to treat amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, a neurodegenerative disease with no effective treatment.
4. Indication:  Investigated for use/treatment in amyotrophic lateral sclerosis (ALS), diabetes mellitus type 2, neurologic disorders, and neuropathy (diabetic).
DrugId:  16
1. Name:  PYM50018
2. Groups:  Investigational
3. Description:  PYM50018 is a patented, orally active, neuroprotective and neuroregenerative compound. It is developed for the treatment of amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's disease). In pre-clinical models, PYM50018 has been observed to protect against neuronal damage, increase neurite outgrowth, reverse oxidative damage and reverse neuronal apoptosis in vitro. When administered orally to a transgenic pre-clinical model of ALS, PYM50018 delays the loss of muscle strength and extends survival time.
4. Indication:  Investigated for use/treatment in amyotrophic lateral sclerosis (ALS).
DrugId:  17
1. Name:  Creatinine
2. Groups:  Investigational
3. Description:  Creatinine has been used in trials studying the treatment of Amyotrophic Lateral Sclerosis.
4. Indication:  Not Available
DrugId:  18
1. Name:  Arundic acid
2. Groups:  Investigational
3. Description:  Arundic acid has been investigated for the treatment of Amyotrophic Lateral Sclerosis (ALS).
4. Indication:  Investigated for use/treatment in cerebral ischemia.
DrugId:  19
1. Name:  Cabozantinib
2. Groups:  Approved, Investigational
3. Description:  Cabozantinib was approved in 2012 and is a non-specific tyrosine kinase inhibitor. It is marketed as Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. It's label includes a black box warning of gastrointestinal perforations, fistulas, and hemorrhage. The FDA approved cabozantinib as Cabometyx for patients with advanced renal cell carcinoma in April 2016.
4. Indication:  For the treatment of metastatic medullary thyroid cancer and for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy.
DrugId:  20
1. Name:  VP025
2. Groups:  Investigational
3. Description:  VP025, a novel drug formulation based on phospholipid microparticles incorporating phosphatidylglycerol, can inhibit neuroinflammation. VP025 may inhibit immune system activation and protect motoneurons from injury. It also shows the ability to reduce inflammation across the blood-brain barrier and improve correlates of memory and learning function. It is being developed to target the chronic inflammation within the central nervous system that is associated with a number of neurological diseases, including Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (Lou Gehrig’s disease). It is considered to be a systemic anti-inflammatory and neuroprotective agent.
4. Indication:  Investigated for use/treatment in alzheimer's disease and inflammatory disorders (unspecified).
DrugId:  21
1. Name:  Tazemetostat
2. Groups:  Investigational
3. Description:  Tazemetostat has been used in trials studying the treatment of Rhabdoid Tumors, Synovial Sarcoma, Epithelioid sarcoma, INI1-negative Tumors, and Renal Medullary Carcinoma, among others.
4. Indication:  Not Available
DrugId:  22
1. Name:  Pipazethate
2. Groups:  Approved
3. Description:  A non-narcotic oral antitussive agent.
4. Indication:  For the treatment of cough.
DrugId:  23
1. Name:  Autologous cultured chondrocytes
2. Groups:  Approved
3. Description:  Autologous cultured chrondrocytes are used as autologous cell therapy to repair articular cartilage injuries in the knee (femoral condyle) due to acute or repetitive trauma. It serves as an alternative repair treatment for patients with inadequate response to pre-existing surgical methods. The surgical implantation shows a tolerable safety profile and efficacy up to 4 years, but it is not indicated for patients with osteoarthritis. It has been used since 1995 as Carticel and gained biologic license in 1997. The surgical implantation was first performed in Sweden.
4. Indication:  Cellular repair strategy for patients with symptomatic cartilage defects of the femoral condyle (medial, lateral or trochlea) caused by trauma or patients who were previously unresponsive to available surgical procedures. 
DrugId:  24
1. Name:  TD-2749
2. Groups:  Investigational
3. Description:  TD-2749 is selective 5-HT4 agonists discovered by Theravance through the application of multivalent drug design in a drug discovery program dedicated to finding new medicines for GI motility disorders such as chronic constipation, constipation-predominant irritable bowel syndrome (C-IBS), opioid-induced constipation, functional dyspepsia and diabetic gastroparesis.
4. Indication:  Investigated for use/treatment in constipation, gastrointestinal diseases and disorders (miscellaneous), gastroparesis, and irritable bowel syndrome (IBS).
DrugId:  25
1. Name:  Xaliproden
2. Groups:  Investigational
3. Description:  Not Available
4. Indication:  Investigated for use/treatment in amyotrophic lateral sclerosis (ALS) and alzheimer's disease.
